Evaluating Paxlovid for treating hospitalized COVID-19 patients
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
This study is testing how well Paxlovid works and its safety for people hospitalized with COVID-19 by looking at their medical records.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05387369 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the efficacy and safety of Paxlovid in hospitalized patients diagnosed with COVID-19. It will collect and review medical records of patients treated with Paxlovid at Huashan Hospital from 2022 to 2027, focusing on demographic data, clinical characteristics, laboratory results, treatment history, adverse reactions, and outcomes. The goal is to assess how effective Paxlovid is and identify factors that may influence the prognosis of COVID-19.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized patients with a confirmed positive SARS-CoV-2 test and experiencing mild to moderate COVID-19 symptoms.
Not a fit: Patients with severe COVID-19 symptoms or those not hospitalized may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Paxlovid for hospitalized COVID-19 patients, potentially improving treatment protocols.
How similar studies have performed: Other studies have shown promising results with Paxlovid in treating COVID-19, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who have a positive SARS-CoV-2 test result; * Participants who have one or more mild or moderate COVID-19 symptoms. Exclusion Criteria: * No specific exclusion criteria in this real world study.
Where this trial is running
Shanghai
- Huashan Hospital Affiliated to Fudan University — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Feng Sun, MD — Huashan Hospital affliatied to Fudan University
- Study coordinator: Feng Sun, MD
- Email: aaronsf1125@126.com
- Phone: +86 02152889999
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.